Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
Private Equity 13
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Partnerships 14
Bioheart Forms Joint Venture with Walter Bell 14
Licensing Agreements 15
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
Debt Offering 18
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Acquisition 28
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc – Key Competitors 30
U.S. Stem Cell Inc – Key Employees 31
U.S. Stem Cell Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: USRM posts 25% nine month revenue increase from 3Q 2017 33
Aug 08, 2018: USRM posts profitable results for second quarter 2018 34
May 09, 2018: U.S. Stem Cell Reports First Quarter Results 35
Apr 16, 2018: USRM Reports 2017 Financial Results 36
Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company’s History 37
Corporate Communications 38
Sep 11, 2018: USRM hires senior VP of US & international sales 38
Legal and Regulatory 39
Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 39
Product News 40
Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 40
Other Significant Developments 42
Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 42
Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 43
Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Bioheart Forms Joint Venture with Walter Bell 14
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc, Key Competitors 30
U.S. Stem Cell Inc, Key Employees 31
U.S. Stem Cell Inc, Joint Venture 32
List of Figures
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10